Predicting virus filtration performance with virus spike characterization

BioProcess International

Volumn 9, Issue 3, 2011, Pages 26-36

  Asher, Damon R ^a   Slocum, Ashley L ^b   Bergmann, Katherine F ^c   Genest, Paul ^d   Katz, Amanda B ^a   Morais, Jason J ^e   Lawrence, Catherine M ^e   Greenhalgh, Patricia ^a  

^a Bioprocess R and D Virology Group   (United States)

^b Biomanufacturing Sciences Network   (United States)

^c Lancaster Laboratories   (United States)

^d EMD Millipore Biomanufacturing Sciences Network   (United States)

^e GENZYME CORPORATION   (United States)

Author keywords

Contamination control; Filtration; Viral clearance; Virus spiking

Indexed keywords

MONOCLONAL ANTIBODY;

ANTIBODY TITER; BIOFOULING; CHROMATOGRAPHY; DEVICE; FILTER DESIGN; FILTRATION; FLUID FLOW; HIGH THROUGHPUT SCREENING; HYDRAULIC PERMEABILITY; MASS SPECTROMETRY; MEMBRANE CHROMATOGRAPHY; MEMBRANE FILTER; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRODUCT SAFETY; PROTEIN ANALYSIS; PROTEIN INTERACTION; REVIEW; ULTRACENTRIFUGATION; VIRAL CLEARANCE; VIRUS CHARACTERIZATION; VIRUS FILTER; VIRUS LOAD; VIRUS PARTICLE; VIRUS PURIFICATION;

EID: 79952649587     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (13)

1. Bolton G, et al. Normal-Flow Virus Filtration: Detection and Assessment of the Endpoint in Bioprocessing. Biotechnol. Appl. Biochem. 42, 2005:133-142.
2. Cabatingan, M. Impact of Virus Stock Quality on Virus Filter Validation. BioProcess Int. 3(7) 2005: S39-S43.
3. Denton A, Jones C, Tarrach K. Integration of Large-Scale Chromatography with Nanofiltration for an Ovine Polyclonal Product. Pharm. Technol. 33(1) 2009: 62-70.
4. Khan NZ, et al. Filter Preconditioning Enables Representative Scaled-Down Modeling of Filter Capacity and Viral Clearance By Mitigating the Impact of Virus Spike Impurities. Biotechnol. Appl. Biochem. 52(Pt 4) 2009: 293-301.
5. Lute S, et al. Phage Passage After Extended Processing in Small-Virus-Retentive Filters. Biotechnol. Appl. Biochem. 47(Pt 3) 2007: 141-51. Erratum in: Biotechnol Appl. Biochem. 48(Pt 1) 2007: 63.
6. Wu Y, et al. Validation of Adventitious Virus Removal By Virus Filtration. BioProcess Int. 6(5) 2009: 54-59.
7. Garnick RL. Experience with Viral Contamination in Cell Culture. Dev. Biol. Stand. 88, 1996: 49-56.
8. Garnick RL. Raw Materials As a Source of Contamination in Large-Scale Cell Culture. Dev. Biol. Stand. 93, 1998: 21-29.
9. Technical Report No. 47: Preparation of Virus Spikes Used for Virus Clearance Studies. Parenteral Drug Association. 2010.
10. Astell CR, et al. The Complete DNA Sequence of Minute Virus of Mice: An Autonomous Parvovirus. Nucleic Acids R)es. 11(4) 1983: 999-1018.
11. Willwand K, and Hirt B. The Major Capsid Protein VP2 of Minute Virus of Mice (MVM) Can Form Particles Which Bind to the 3′-Terminal Hairpin of MVM Replicative-Form DNA and Package Single-Stranded Viral Progeny DNA. J. Virol. 67(9) 1993: 5660-5663. (Pubitemid 23241405)
12. ICH, Harmonized Tripartate Guideline: Q5A Viral Safety of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. Fed. Reg. 63(185) 24 September 1998: 51074; www.ich.org/LOB/media/MEDIA425.pdf.
13. The European Agency for the Evaluation of Medicinal Products (EMEA), Human Medicines Evaluation Unit CPMP Biotechnology Working Party. Note for Guidance on Virus Validation Studies: The Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses. CPMP/BWP/268/95, revised 1996.